Your browser doesn't support javascript.
loading
Relationships between Indicators of Lower Extremity Artery Disease and miRNA Expression in Peripheral Blood Mononuclear Cells.
Zalewski, Daniel P; Ruszel, Karol P; Stepniewski, Andrzej; Galkowski, Dariusz; Feldo, Marcin; Kocki, Janusz; Bogucka-Kocka, Anna.
  • Zalewski DP; Chair and Department of Biology and Genetics, Medical University of Lublin, 4a Chodzki St., 20-093 Lublin, Poland.
  • Ruszel KP; Department of Clinical Genetics, Chair of Medical Genetics, Medical University of Lublin, 11 Radziwillowska St., 20-080 Lublin, Poland.
  • Stepniewski A; Ecotech Complex Analytical and Programme Centre for Advanced Environmentally Friendly Technologies, University of Marie Curie-Sklodowska, 39 Gleboka St., 20-612 Lublin, Poland.
  • Galkowski D; Department of Pathology and Laboratory Medicine, Rutgers-Robert Wood Johnson Medical School, One Robert Wood Johnson Place, New Brunswick, NJ 08903-0019, USA.
  • Feldo M; Chair and Department of Vascular Surgery and Angiology, Medical University of Lublin, 11 Staszica St., 20-081 Lublin, Poland.
  • Kocki J; Department of Clinical Genetics, Chair of Medical Genetics, Medical University of Lublin, 11 Radziwillowska St., 20-080 Lublin, Poland.
  • Bogucka-Kocka A; Chair and Department of Biology and Genetics, Medical University of Lublin, 4a Chodzki St., 20-093 Lublin, Poland.
J Clin Med ; 11(6)2022 Mar 15.
Article en En | MEDLINE | ID: mdl-35329950
ABSTRACT
Lower extremity artery disease (LEAD) is an underdiagnosed and globally underestimated vascular disease caused by the progressive and chronic formation of atherosclerotic plaques in the arteries of the lower limbs. Much evidence indicates that the abnormal course of pathophysiological processes underlying LEAD development is associated with altered miRNA modulatory function. In the presented study, relationships between miRNA expression and clinical indicators of this disease (ABI, claudication distance, length of arterial occlusion, Rutherford category, and plaque localization) were identified. MiRNA expression profiles were obtained using next-generation sequencing in peripheral blood mononuclear cells (PBMCs) of 40 LEAD patients. Correlation analysis performed using the Spearman rank correlation test revealed miRNAs related to ABI, claudication distance, and length of arterial occlusion. In the DESeq2 analysis, five miRNAs were found to be dysregulated in patients with Rutherford category 3 compared to patients with Rutherford category 2. No miRNAs were found to be differentially expressed between patients with different plaque localizations. Functional analysis performed using the miRNet 2.0 website tool determined associations of selected miRNAs with processes underlying vascular pathology, such as vascular smooth muscle cell differentiation, endothelial cell apoptosis, response to hypoxia, inflammation, lipid metabolism, and circadian rhythm. The most enriched functional terms for genes targeted by associated miRNAs were linked to regulation of the cell cycle, regulation of the transcription process, and nuclear cellular compartment. In conclusion, dysregulations of miRNA expression in PBMCs of patients with LEAD are indicative of the disease and could potentially be used in the prediction of LEAD progression.
Palabras clave